Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41579-020-00462-y http://scihub22266oqcxt.onion/10.1038/s41579-020-00462-y 33067570!7566580!33067570     free     free     free       Nat+Rev+Microbiol 2021 ; 19 (3): 211-219 Nephropedia Template TP {{tp|p=33067570|t=2021. Learning from the past: development of safe and effective COVID-19 vaccines |pdf=|usr=}}{{33067570}} gab.com Text Learning from the past: development of safe and effective COVID-19 vaccines JO: Nat Rev Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33067570 #FOAvip The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited an equally rapid response aiming to develop a COVID-19 vaccine. These efforts are encouraging; however, comprehensive efficacy and safety evaluations are essential in the development of a vaccine, and we can learn from previous vaccine development campaigns. In this Perspective, we summarize examples of vaccine-associated disease enhancement in the history of developing vaccines against respiratory syncytial virus, dengue virus, SARS-CoV and Middle East respiratory syndrome coronavirus, which highlight the importance of a robust safety and efficacy profile, and present recommendations for preclinical and clinical evaluation of COVID-19 vaccine candidates as well as for vaccine design and optimization. Twit Text FOAVip Learning from the past: development of safe and effective COVID-19 vaccines ????Nat Rev Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33067570 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33067570 #FOAvip English Wikipedia <ref>{{Cite pmid|33067570}}</ref> Learning from the past: development of safe and effective COVID-19 vaccines #MMPMID33067570 Su S; Du L; Jiang S Nat Rev Microbiol 2021[Mar]; 19 (3): 211-219 PMID33067570show ga The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited an equally rapid response aiming to develop a COVID-19 vaccine. These efforts are encouraging; however, comprehensive efficacy and safety evaluations are essential in the development of a vaccine, and we can learn from previous vaccine development campaigns. In this Perspective, we summarize examples of vaccine-associated disease enhancement in the history of developing vaccines against respiratory syncytial virus, dengue virus, SARS-CoV and Middle East respiratory syndrome coronavirus, which highlight the importance of a robust safety and efficacy profile, and present recommendations for preclinical and clinical evaluation of COVID-19 vaccine candidates as well as for vaccine design and optimization. |*COVID-19 Vaccines/administration & dosage/adverse effects/immunology[MESH] |COVID-19/immunology/prevention & control[MESH] |Clinical Trials as Topic[MESH] |Drug Design[MESH] |Drug Evaluation[MESH] |Drug Industry[MESH] |Humans[MESH] |Respiratory Syncytial Virus Vaccines/immunology[MESH]Learning from the past: development of safe and effective COVID-19 vac(epmc).pdf DeepDyve Pubget Overpricing